UBA1 inhibition contributes radiosensitization of glioblastoma cells via blocking DNA damage repair
Glioblastoma multiforme (GBM) is a brain tumor with high mortality and recurrence rate. Radiotherapy and chemotherapy after surgery are the main treatment options available for GBM. However, patients with glioblastoma have a grave prognosis. The major reason is that most GBM patients are resistant t...
Main Authors: | Changyong Wu, Yang Shen, Lin Shi, Junhao Zhang, Tongxuan Guo, Lingni Zhou, Wanzhou Wang, Xu Zhang, Rutong Yu, Xuejiao Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1073929/full |
Similar Items
-
Preclinical evaluation of Mito-LND, a targeting mitochondrial metabolism inhibitor, for glioblastoma treatment
by: Tongxuan Guo, et al.
Published: (2023-08-01) -
GRP78 blockade overcomes intrinsic resistance to UBA1 inhibitor TAK-243 in glioblastoma
by: Xu Zhang, et al.
Published: (2022-03-01) -
ABCB1 limits the cytotoxic activity of TAK-243, an inhibitor of the ubiquitin-activating enzyme UBA1
by: Zhuoxun Wu, et al.
Published: (2022-01-01) -
RETRACTED ARTICLE: GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death
by: Guanzheng Liu, et al.
Published: (2021-07-01) -
Retraction Note: GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death
by: Guanzheng Liu, et al.
Published: (2024-03-01)